QuotedData

Quoted Data

sign up for emailed equity research
Quick  |   Customised Register
Latest News

Biotech and Healthcare News

Worldwide health adds to positions in Mylan and ThemoFisher

Worldwide health adds to positions in Mylan and ThemoFisher

Worldwide health adds to positions in Mylan and ThemoFisher Worldwide Healthcare Trust (WWH) has added two new positions into its top 10 by increasing stakes held in Mylan, a US-based generics/speciality pharmaceuticals company, and ...

Sensyne Health drives WPCT GAV rise in August

Sensyne Health drives WPCT GAV rise in August

Sensyne Health drives WPCT GAV rise in August Woodford Patient Capital Trust (WPCT)'s investment in Sensyne Health, the UK healthcare AI firm that completed an IPO last month, appears to be ...

BioPharma Credit extends loan to Amicus

BioPharma Credit extends loan to Amicus

BioPharma Credit extends loan to Amicus BioPharma Credit (BCPR) has entered into a $150m, five-year loan agreement with Amicus Therapeutics, a US-based biotech focused on rare disease. The senior secured loan will ...

PCGH buys J&J, Amgen in latest portfolio update

PCGH buys J&J, Amgen in latest portfolio update

PGCH buys J&J, Amgen in latest portfolio update Polar Capital Global Healthcare Trust (PCGH) has bought a significant new position in the diversified US healthcare giant Johnson & Johnson (J&J), representing ...

IBT portfolio rejig brings Incyte into top 10

IBT portfolio rejig brings Incyte into top 10

IBT portfolio rejig brings Incyte into top 10 International Biotechnology Trust (IBT) gained two new top 10 positions in the form of Incyte and Stemline Therapeutics in August, while seeing Morphosys ...

HBM-backed Argenx reports positive results in ITP, plans new studies

HBM-backed Argenx reports positive results in ITP, plans new studies

HBM-backed Argenx reports positive results in ITP, plans new studies HBM Healthcare-backed Argenx (Euronext & Nasdaq:ARGX) reported a positive Phase II study for its lead product, efgartigimod, in immune thrombocytopaenia (ITP) ...

HBM books profit on Principia IPO

HBM books profit on Principia IPO

HBM books quick profit on Principia IPO Swiss biotech investment trust, HBM Healthcare (HBMN) should be able to book a tidy CHF18m profit - equivalent to a CHF2.58/share (+1.5%) rise in ...

EADV data validate JAK inhibitors in eczema

EADV data validates JAK inhibitors in eczema Data disclosed at a scientific conference have added to the evidence supporting JAK inhibition in atopic dermatitis (eczema), but various trial differences do not yet allow a ...

Pfizer reports positive results for JAK/TYK2 assets in alopecia

Pfizer reports positive results for JAK/TYK2 assets in alopecia

Pfizer reports positive results for JAK/TYK2 assets in alopecia Pfizer has announced positive results from a Phase IIa study that examined, in parallel, the efficacy of its JAK3 inhibitor, PF-06651600, and ...

BMS results validate TYK2 approach in psoriasis

BMS results validate TYK2 approach in psoriasis

BMS results validate TYK2 approach in psoriasis Promising results from a mid-stage study of Bristol-Myers Squibb's tyrosine kinase 2 (TYK2) inhibitor, BMS-986165, validate this new mechanism in psoriasis, its lead indication, ...

Contact us

captcha